Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002871 (anemia)
 52,094 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Efficiency of anti-anemic drug Ferrum Lack when using it alone or together with enterosorbent Uvesorb has been studied on the model of iron deficiency anemia (IDA) in pregnant rats. It is stated that three-fold blood-letting in total volume of 6 ml carried out prior to pregnancy causes symptoms of IDA. Over a period of the whole pregnancy the concentration of hemoglobin and the concentration of erythrocytes were lower than in intact pregnant rats. Tissue hypoxia characterized by disturbance of terminal microcirculation, capillary tissue diffusion and oxygen utilization was observed in pregnant rats with anemia model. Dysfunctional shifts in the system lipid peroxidation (LPO)-antioxidant protection (AOP) as noncompensated process of free-radical oxidation of lipids were revealed in parallel. A comparative estimation of results from treatment in groups of animals which were given and not given enterosorbent Uvesorb together with anti-anemic drug Ferrum Lack permitted determining the presence of anti-anemic and antihypoxic effects in both groups, though the latter was more pronounced in animals which were given enterosorbent. Various results were revealed relative to changes in the LPO-AOP system. When using drug Ferrum Lack alone, the content of products of LPO-lipid hydroperoxides and malonic dialdehyde increased in blood, whereas in group of animals which were given enterosorbent the number of these products was observed to significantly decrease.
 ...
PMID:[Experimental study on efficiency of enterosorbents in the combined treatment of iron-deficiency anemia in pregnancy]. 134 Apr 51

Summation of negative effects of hypoxia and lysosome-tropic properties of Ferrum Lec was observed in patients with severe stage of iron-deficiency anemia (IDA), and in rabbits with experimental IDA, during treatment by intravenous injections of Ferrum Lec. These effects were expressed in exageration of the destabilizing action of hypoxia on lysosome membranes, and attended by a significant rise in the lysosomal enzyme levels of blood plasma, by the development of dystrophic processes in hepatocytes, and by a decrease in the number of sinusoidal cells. All these facts should be considered in clinical practice.
 ...
PMID:[Adverse effects of Ferrum Lec (clinico-experimental study)]. 149 May 67

The development of secondary anaemia is a constant associated phenomenon of chronic renal failure. During its treatment by recombinant human erythropoietin (rHuEPO) erythropoiesis is accelerated and this increases demands on the supply of dietary erythropoietic precursors (Fe, pyridoxine, folic acid, vitamin B12). In particular as regards iron, frequently the dietary amount is not sufficient and supplementation is necessary. The objective of the present work is to compare oral and intravenous iron supplementation in the treatment of secondary anaemia by rHuEPO in patients with chronic renal failure treated by haemodialysis. A group of haemodialyzed patients (n = 61) treated with erythropoietin, where the serum ferritin concentration had dropped beneath 300 ng/ml, or the transferrin concentration below 0.20 was divided at random into two sub-groups. To group "A" Actiferrin was administered 3 x 1 cps/d (Ferrosi sulfas heptahydricus, corresponding to 34.5 mg elemental Fe and serine 129 mg per capsule, i.e. a total of 724.5 mg elemental Fe per week). To group "A" Ferrum-Lek was administered 1 vial per week by the i.v. route (Ferri oxidum saccharatum, corresponding to 100 mg elemental iron per week). The two groups were comparable as to the mean erythropoietin dose (50 U/kg per week) and the patients' mean age (61 years), the male/female ratio and the spectrum of basic diseases. After six weeks of treatment a comparable increase of the haematocrit and serum iron concentration was observed in both groups. As to transferrin saturation, there was a more marked increment in the intravenously supplemented group. The serum ferritin values in group "A" declined, while in group "F" they increased. After both types of iron supplementation a comparable increase of the haematocrit and serum iron concentration occurred, the iron reserves represented by serum ferritin differed however and from the long-term aspect they are in favour of intravenous iron supplementation in haemodialyzed patients treated with erythropoietin.
 ...
PMID:[Iron supplementation during erythropoietin therapy in patients on hemodialysis]. 907 85

Anaemia is the most common medical disorder in pregnancy with iron deficiency anaemia accounting for the majority of cases. Over 90% of the iron deficiency anaemia is due to red cell iron deficiency associated with depleted iron stores and deficient intake. The two main modalities of treating iron deficiency anaemia are oral or parenteral iron. Ferrous Hausmann (iron dextrin) is the latest iron preparation which can be used for intravenous parenteral administration as a total dose infusion. This study compares the efficacy of Ferrum Hausmann with oral ferrous fumarate therapy in the treatment of iron deficiency anaemia in pregnancy. Our study shows that treatment with intravenous Ferrum Hausmann (iron dextrin) resulted in a significantly better level and rate of increase of haemoglobin (p<0.001). Serum ferritin, which is the best indicator of iron stores, was significantly higher (p<0.001) in the intravenous group. Other indices of iron status such as serum iron, serum transferrin and zinc protoporphyrin also showed a significant improvement in the intravenous group compared to those given oral iron. The results suggest that intravenous iron as a total dose infusion is able to replenish iron stores more efficiently, completely and at a faster rate than oral iron therapy, thus providing the fuel for stimulation of full erythopoiesis compared to oral iron. There were also no reports of any adverse reactions with intravenous iron dextrin, whereas there were a considerable proportion of women on oral iron therapy who reported side effects. In conclusion, intravenous iron therapy with Ferrous Hausmann (iron dextrin) is a suitable, effective and safe alternative to oral iron therapy in the treatment of iron deficiency anaemia in pregnancy.
 ...
PMID:A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. 1077

In order to study iron metabolism disorders in patients with portal hypertension syndrome, to determine clinical significance of hyposiderosis and to work out effective method of its correction, 94 patients with cirrhosis of the liver complicated by portal hypertension were examined. As a result of determination of these disorders of iron metabolism methods for treatment of hypochromal anemia and hyposiderosis have been worked out. Hemotransfusions, administration of iron-containing preparation Ferrum-lec and combination of these methods were used for treatment. It was established that administration of large doses of iron-containing preparation Ferrum-lec substantially contributed to improvement of iron metabolism in patients with cirrhosis of the liver and extrahepatic portal hypertension, to reduction of postoperative complications rate and to upgrading the results of surgical treatment.
 ...
PMID:[Pre- and postoperative correction of hyposiderosis in surgical treatment of portal hypertension]. 964 53

Iron-deficiency anemia (IDA) is the most common nutritional deficiency in childhood throughout the world. Although it has been shown that IRA is associated with elevated plasma copper and depleted zinc levels in children, there are conflicting results on the effect of iron supplementation on the absorption of these elements. The aim of this study was to investigate the effects of ferrous and ferric iron supplementation on the trace element status in children (n=25, aged 8-168 mo) with IDA. Fourteen of them were treated with ferric hydroxide-polymaltose complex (Ferrum, Vifor, Switzerland) (6 mg/d in the first 3 mo for initial therapy and 3 mg/kg for 3 mo as maintenance); the others were treated with a ferrous sulfate complex (FerroSanol, Schwarz, Germany) (6 mg/d in the first 3 mo for initial therapy and 3 mg/kg for 3 mo as maintenance). Plasma copper, zinc, and ceruloplasmin levels as well as hematological parameters were determined at baseline and the first, third, and sixth month of the treatment period. The hemoglobin and iron levels of patients in both groups were higher in the first and sixth months compared to baseline. Although the ceruloplasmin levels were depleted (48.9 mg/dL vs 41.4 mg/dL, p=0.035) during ferrous iron treatment, the copper and zinc levels remained unchanged. On the other hand, ferric iron supplementation led to an increase in zinc levels in the sixth month of treatment (0.77 mg/L vs 1.0 mg/L, p=0.021). The plasma copper levels were lower in the ferrous iron-treated group at the end of the first month of treatment than in the ferric irontreated group (1.06 mg/L vs 1.29 mg/L, p=0.008). In conclusion, our data showed that copper and ceruloplasmin metabolisms were affected by ferrous iron supplementation, whereas ferric iron kept them to normal levels of zinc, possibly by affecting their absorption. We conclude that the copper and zinc status of patients with IDA should be taken into consideration before and after iron therapy.
 ...
PMID:Effects of iron(II) salts and iron(III) complexes on trace element status in children with iron-deficiency anemia. 1290 30

In the US, 70% of pregnant women use an iron-containing prenatal supplement product; however, only 2.6% of pregnant women have iron-deficiency anemia and 16.3% are iron deficient. Yet, published data on the amounts and chemical forms of iron used in formulating these products are not available, although they are known to affect bioavailability. This information is especially important in comparing commercially available products with those that were tested in clinical trials. Our examination of nonprescription and prescription iron-containing prenatal supplement products in NIH's Dietary Supplement Label Database (DSLD) and DailyMed found the labeled amount of elemental iron ranged between 9 and 60 mg/serving in 148 nonprescription supplements and between 4.5 and 106 mg/serving in 101 prescription supplements. Ferrous fumarate was the preferred chemical form used in these products. In contrast, ferrous sulfate was the preferred chemical form of iron reported in the clinical trials summarized in a 2015 Cochrane Systematic review assessing the effects of daily oral iron supplements for pregnant women. Ferrous sulfate was not found on any prenatal supplement product label in the DSLD or DailyMed. The chemical forms of products on the market and those tested in clinical trials are dissimilar, and we believe this may have clinical implications. The findings raise several questions. Do outcomes in clinical trials correlate with the benefits and risks that might adhere to iron supplements with different iron formulations? Should the differences in chemical forms, their bioavailability, and safety profiles, be considered in greater depth when evaluating the effect of the various formulations on maternal iron nutriture? Should new clinical trials for pregnant and lactating women in the US use a form of iron not found in prenatal supplements sold in the US or should a more common form be used?
 ...
PMID:The Chemical Forms of Iron in Commercial Prenatal Supplements Are Not Always the Same as Those Tested in Clinical Trials. 3114 13

Iron-deficiency anemia is an important health problem in global public issues, and development of iron fortifiers in diets is essential for the decrease of iron deficiency. However, there are problems for iron fortification in food because the common bioavailable iron compounds would contribute to iron-promoted lipid oxidation and unpleasant iron odor, presenting an adverse food quality. Ferrous fumarate loaded microstructured gel beads were prepared by an emulsification-gelation method using an alginate-caseinate matrix, and the gel network was formed by crosslinking of Ca2+ or Fe2+. Internal gelated beads showed relatively symmetrical and homogeneous spheres with no adhesion due to the simultaneous release of Fe2+ to initiate gelation in situ. External gelated beads displayed an irregular and adhesive structure, probably because the random contact between Na-ALG and Ca2+ occurred on the droplet surface, and the immediately gelated hardening layer provided a delay for further Ca2+ diffusion. The gel beads exhibited a lag phase in the promotion of lipid oxidation of the emulsion and restrained the iron odor release from ferrous fumarate. Ferrous ion release from microstructured gel beads in the simulated gastric juice was obviously delayed before a more progressive high release in the simulated intestinal juice, beneficial for iron absorption in the duodenum. The iron encapsulated microstructured gel beads might be developed as a promising safe iron fortifier by relieving lipid oxidation and iron odor.
 ...
PMID:Iron encapsulated microstructured gel beads using an emulsification-gelation technique for an alginate-caseinate matrix. 3232 95